8-K: Alphatec Holdings Reports Strong Q1 2025 Results, Raises Full-Year Guidance

Alphatec Holdings announces positive Q1 2025 financial results, including a 22% increase in total revenue, and raises its full-year revenue and profitability guidance.

Summary

• Alphatec Holdings, Inc. (ATEC) reported its financial results for the quarter ended March 31, 2025.
• Total revenue for Q1 2025 was $169 million, representing a 22% increase year-over-year.
• Surgical revenue grew by 24% to $152 million, driven by a 17% increase in procedural volume.
• GAAP gross margin was 69%, while non-GAAP gross margin was 70%.
• GAAP operating expenses were $160 million, and non-GAAP operating expenses were $124 million.
• The company reported a GAAP net loss of $52 million.
• Adjusted EBITDA was $11 million, with an adjusted EBITDA margin of 6%.
• ATEC successfully refinanced its convertible debt to a 2030 maturity.
• The company is raising its full-year 2025 revenue guidance to $734 million, reflecting 20% growth.
• The company now expects non-GAAP adjusted EBITDA of approximately $78 million for the full year 2025.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, improved profitability, and increased guidance. The successful debt refinancing further strengthens the company's financial position.

Positives

• ATEC reported a 22% increase in total revenue for Q1 2025.
• Surgical revenue grew by 24%, driven by procedural volume growth.
• The company improved its Adjusted EBITDA margin by 840 bps year-over-year.
• ATEC raised its full-year revenue guidance to $734 million.
• The company raised its full-year non-GAAP adjusted EBITDA guidance to approximately $78 million.
• ATEC achieved 18% growth in new surgeon adoption.
• The company successfully refinanced convertible debt to 2030 maturity.
• Free cash use improved by $55 million compared to the first quarter of 2024.

Negatives

• The company reported a GAAP net loss of $52 million for Q1 2025.
• GAAP operating expenses were $160 million.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• These risks include the uncertainty of success in developing new products, the ability to execute the strategic operating plan, and the acceptance of the company's products by the surgeon community.
• Other risks include failure to obtain regulatory clearance, continuation of favorable third-party reimbursement, unanticipated expenses, product liability exposure, and patent infringement claims.

Future Outlook

The company expects total revenue to grow 20% to $734 million for the full year 2025, including surgical revenue of $658 million and EOS revenue of $76 million. The company also expects non-GAAP adjusted EBITDA of approximately $78 million for the full year 2025.

Management Comments

• ATEC exists to revolutionize spine surgery, and our Q1 results show that our unique, end-to-end procedural ecosystem is continuing to drive rapid, durable growth, said Pat Miles, Chairman and Chief Executive Officer.
• We are executing with discipline and delivering on our financial commitments, while continuing to invest in differentiated innovation.
• ATECs relentless, spine-only focus has made it the preferred destination.
• We are built to lead and our best is still yet to come.

Industry Context

ATEC's focus on spine surgery and its integrated InformatiX platform positions it to compete effectively in the medical device industry. The company's growth in surgical revenue and new surgeon adoption suggests a strong market position and potential for continued growth.

Comparison to Industry Standards

• Comparing ATEC's 22% revenue growth to competitors like Medtronic (Spine & Biologics division) and NuVasive, which have shown more modest growth, indicates a strong performance.
• ATEC's focus on procedural volume growth (17%) aligns with industry trends emphasizing value-based care and improved patient outcomes.
• The adjusted EBITDA margin of 6% is a key indicator of profitability, and the 840 bps year-over-year improvement suggests effective cost management.
• The successful refinancing of convertible debt to 2030 provides financial stability and flexibility, similar to what larger companies like Stryker and Johnson & Johnson achieve through their capital management strategies.

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and increased guidance.
• Employees may be motivated by the company's growth and success.
• Customers (surgeons) may be encouraged by the company's innovation and commitment to spine surgery.
• Suppliers may benefit from the company's increased revenue and production volume.
• Creditors may view the company's financial performance and debt refinancing favorably.

Next Steps

• The company will present these results via a live webcast today at 1:30 p.m. PT / 4:30 p.m. ET.
• A replay of the webcast will remain available through the Investor Relations Section of ATECs Corporate Website for twelve months.

Key Dates

Keywords

Alphatec Holdings, ATEC, spine surgery, financial results, revenue, EBITDA, guidance, surgical revenue, spine